Dow Jones Newswires: AstraZeneca Reports ‘Historic' Trial Results for Enhertu Cancer TreatmentMarket Watch • 02/22/22
AstraZeneca's Enhertu shown to improve survival in breast cancer patients in pivotal trialProactive Investors • 02/21/22
ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 02/21/22
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: ReutersBenzinga • 02/16/22
AstraZeneca EU wins approval for the first drug in more than a decade for lupusProactive Investors • 02/16/22
London Markets: London stocks join global bounce, with AstraZeneca leading on positive drug newsMarket Watch • 02/15/22
AstraZeneca drug could help prolong life of terminally ill prostate cancer patientsProactive Investors • 02/15/22
Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in ColombiaPRNewsWire • 02/14/22
AstraZeneca PLC (AZN) CEO Pascal Soriot on Q4 2021 Results - Earning Call TranscriptSeeking Alpha • 02/11/22
London Markets: AstraZeneca buoys FTSE 100 while Unilever slips on margin guidanceMarket Watch • 02/10/22
AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinetProactive Investors • 02/10/22
AstraZeneca looks beyond Covid, US inflation and Unilever under pressure: Thursday's agendaProactive Investors • 02/09/22